<!DOCTYPE html>
<html>
<head>
    <title>BIOTECHNOLOGY | MAKE IN INDIA</title>
    <!-- meta tags start -->
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="Keywords" content="plank, premium, mobile, template, HTML, Css" />
    <meta name="Description" content="Premium mobile HTML/CSS template." />
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" />
    <!-- meta tags end -->

    <!-- favorite icon starts -->
    <link rel="shortcut icon" href="images/common/favicon.ico" type="image/x-icon" />
    <!-- favorite icon ends -->

    <!-- Google fonts start -->
    <link href='http://fonts.googleapis.com/css?family=Lato:300,400,700,400italic' rel='stylesheet' type='text/css' />
    <!-- Google fonts end -->

    <!-- CSS files start -->
    <link href="css/framework.css" rel="stylesheet" type="text/css" media="all" />
    <link href="css/colorbox.css" rel="stylesheet" type="text/css" media="all" />
    <link href="css/elements.css" rel="stylesheet" type="text/css" media="all" />
    <link href="css/style.css" rel="stylesheet" type="text/css" media="all" />
    <link href="css/responsive.css" rel="stylesheet" type="text/css" media="screen" />
    <link href="css/hidpi.css" rel="stylesheet" type="text/css" media="screen" />
    <link href="css/skin.css" rel="stylesheet" type="text/css" media="all" />
    <link href="css/custom.css" rel="stylesheet" type="text/css" media="all" />
    <!-- CSS files end -->

    <!-- JavaScript files start -->
    <script type="text/javascript" src="js/jquery.min.js"></script>
    <script type="text/javascript" src="js/effects.jquery-ui.min.js"></script>
    <script type="text/javascript" src="js/jquery.nivo-slider.min.js"></script>
    <script type="text/javascript" src="js/jquery.colorbox.min.js"></script>
    <script type="text/javascript" src="js/custom.js"></script>
    <!-- JavaScript files end -->
</head>

<body>
    <!-- website wrapper starts -->
    <div class="websiteWrapper">

        <!-- main menu wrapper starts -->
       
        <!-- main menu wrapper ends -->

        <!-- header wrapper starts -->
        <div class="headerWrapper">
           
        </div>
        <!-- header wrapper ends -->

        <!-- page wrapper starts -->
        <div class="pageWrapper faqPageWrapper">
            <div class="singleProjectImageWrapper">
                <img src="images/sector-icons/sectors-biotech-icon.png" class="singleProjectImage" alt="" />
            </div>
            <!-- page content wrapper starts -->
            <div class="pageContentWrapper">
                <!-- page title starts -->
                <h3 class="pageTitle">BIOTECHNOLOGY</h3>
                <!-- page title ends -->
                <!-- faqs start -->
                <!-- accordion wrapper starts -->
                <div class="accordionWrapper">
                    <!-- accordion item wrapper starts -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">SUMMARY</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">

                                <p>3rd biggest biotech industry in the Asia-Pacific region.</p>
                                <p>2nd highest number of USFDA–approved plants.</p>
                                <p>USD 3.7 Billion to be spent on biotechnology from 2012-17.</p>
                                <p>No. 1 producer of Hepatitis B vaccine recombinant.</p>
                                <p>USD 4.3 Billion bio-economy by the end of 2013.</p>
                                <p>USD 100 Billion industry by 2025.</p>


                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->
                    <!-- accordion item wrapper starts -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">REASONS TO INVEST</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">

                                <p>India is amongst the top 12 biotech destinations in the world and ranks third in the Asia-Pacific region..</p>
                                <p>India has the second-highest number of USFDA–approved plants, after the USA..</p>
                                <p>India adopted the product patent regime in 2005..</p>
                                <p>Increasing government expenditure will augment the growth of the sector — the government aims to spend USD 3.7 Billion on biotechnology between 2012-17..</p>
                                <p>India is the largest producer of recombinant Hepatitis B vaccine..</p>
                                <p>India has the potential to become a major producer of transgenic rice and several genetically modified (GM) or engineered vegetables..</p>



                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->
                    <!-- accordion item wrapper starts -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">STATISTICS</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">

                                <p>The Indian biotech industry will grow at an average growth rate of around 30% a year and reach USD 100 Billion by 2025.</p>
                                <p>The Indian bio-economy grew to USD 4.3 Billion at the end of 2013, up from USD 530 Million in 2003.</p>
                                <p>The Indian biotech industry grew by 15.1% in 2012–13, increasing the market’s revenues from USD 3.31 Billion in 2011-12 to USD 3.81 Billion in 2012–13.</p>
                                <p>The market size of the sector is expected to rise up to USD 11.6 Billion by 2017 due to a range of factors such as growing demand for healthcare services, intensive R&D activities and strong government initiatives.</p>
                                <p>The Indian biotechnology sector is divided into five major segments — bio-pharma, bio-services, bio-agri, bio-industrial and bio-informatics.</p>
                                <p>The bio-pharmaceutical sector accounts for the largest share of the biotech industry with a share of 64% in total revenues in 2013, followed by bio-services (18%), bio-agri (14%), bio-industrial (3%) and bio-informatics (1%).</p>
                                <p>Revenue from bio-pharma exports reached USD 2.2 Billion in 2013, accounting for 51% of total revenues of the biotech industry.</p>



                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->

                    <!-- accordion item wrapper starts -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">GROWTH DRIVERS</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">
                                <p>The sector has seen high growth with a CAGR in excess of 20% and the key drivers for growth in the biotech sector are increasing investments, outsourcing activities, exports and the government’s focus on the sector.</p>
                                <p>A strong pool of scientists and engineers.</p>
                                <p>Cost-effective manufacturing capabilities.</p>
                                <p>The setting up of national research laboratories, centres of academic excellence in biosciences, several medical colleges, educational and training institutes offering degrees and diplomas in biotechnology, bio-informatics and biological sciences.</p>
                                <p>For global companies looking to economise, outsourcing to lower cost economies results in a cost arbitrage of more than 50%.</p>
                                <p>Fast-developing clinical capabilities with the country becoming a popular destination for clinical trials, contract research and manufacturing activities.</p>
                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->

                    <!-- accordion item wrapper starts -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">FDI POLICY</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">
                                <p>Foreign Direct Investment (FDI) up to 100% is permitted through the automatic route for greenfield and through the government route for brownfield, for pharmaceuticals.</p>

                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->


                    <!-- accordion item wrapper starts -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">SECTOR POLICY</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">
                                <h3><strong>National Guidelines for Stem Cell Research 2O13: </strong></h3>
                                <p>The guidelines have been laid down to ensure that research with human stem cells is conducted in a responsible and ethical manner and complies with all regulatory requirements pertaining to biomedical research in general and of stem cell research in particular.</p>
                                <p>These guidelines apply to all stakeholders including individual researchers, organizations, sponsors, oversight/regulatory committees and any other associated with both basic and clinical research on all types of human stem cells and their derivatives.</p>

                                <h3><strong>Guidelines on Similar Biologics-Regulatory Requirements for Marketing Authorization in India 2O12: </strong></h3>
                                <p>The Guidelines on Similar Biologics prepared by the Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) lay down the regulatory pathway for a biologic claiming to be similar to an already authorized reference biologic.</p>
                                <p>The guidelines address the regulatory pathway regarding the manufacturing process and quality aspects for similar biologics.</p>
                                <p>These guidelines also address the pre-market regulatory requirements including a comparability exercise for quality, preclinical and clinical studies and post-market regulatory requirements for similar biologics.</p>
                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->


                    <!-- accordion item wrapper starts -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">FINANCIAL SUPPORT</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">
                                <h3><strong>PROVISIONS OF THE 2O14-2O15 UNION BUDGET :</strong></h3>
                                <p>Service tax exemption for services provided by operators of common bio-medical waste treatment facilities to a clinical establishment by way of treatment or disposal of bio-medical waste or processes incidental thereto.</p>
                                <p>Refund of customs duty paid at the time of import of scientific and technical instruments, apparatus, etc. by public funded and other research institutions, subject to submission of a certificate of registration from the Department of Scientific & Industrial Research.</p>

                                <h3><strong>OTHER INCENTIVES:</strong></h3>

                                <p>Depreciation allowance on plant and machinery has been raised to 40% from 25%.</p>
                                <p>Customs duty exemption on goods imported in certain cases for R&D.</p>
                                <p>Customs and excise duty exemption to recognised Scientific & Industrial Research Organisations (SIRO).</p>
                                <p>150% weighted tax deduction on R&D expenditure.</p>
                                <p>A 3-year excise duty waiver on patented products.</p>
                                <p>100% rebate on own R&D expenditure.</p>
                                <p>125% rebate if research is contracted in publicly-funded R&D institutions.</p>
                                <p>Joint R&D projects are provided with special fiscal benefits.</p>
                                <p>The setting up of a venture capital fund to support small and medium enterprises.</p>
                                <p>Promoting innovations through BIPP, SBIRI, BIRAC and biotech parks.</p>


                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->
                    <!-- accordion item wrapper start -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">INVESTMENT OPPORTUNITIES</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">

                                <p>The Department of Biotechnology has established biotech parks in various parts of the country to facilitate product development, research and innovation, and the development of biotechnology industrial clusters.</p>
                                <p>Operational biotech parks are located at Lucknow in Uttar Pradesh, Bangalore in Karnataka, Kalamassery and Kochi in Kerala, Guwahati in Assam and Chindwara in Madhya Pradesh.</p>
                                <p>The parks offer investors incubator facilities, pilot plant facilities for solvent extraction and laboratory and office spaces.</p>
                                <p>India constitutes around 8% of the total global generics market, by volume, indicating a huge untapped opportunity in the sector.</p>
                                <p>Outsourcing to India is projected to spike up after the discovery and manufacture of formulations.</p>
                                <p>Hybrid seeds, including GM seeds, represent new business opportunities in India based on yield improvement.</p>


                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->
                    <!-- accordion item wrapper start -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">FOREIGN INVESTORS</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">

                                <p>Limagrain (France)</p>
                                <p>Endo Pharmaceuticals (USA)</p>
                                <p>Mylan Inc. (USA)</p>
                                <p>Sanofi Aventis (France)</p>
                                <p>Abbot Laboratories (USA)</p>
                                <p>Fresenius (Singapore)</p>
                                <p>Hospira (USA)</p>


                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->
                    <!-- accordion item wrapper start -->
                    <div class="accordionItemWrapper"> <a href="#" class="accordionButton"><span class="accordionButtonIcon"></span><span class="accordionButtonTitle">AGENCIES</span></a>
                        <div class="accordionContentWrapper">
                            <div class="accordionContent">
                                <p><a href="http://dbtindia.nic.in" target="_blank"> The Department of Biotechnology, Ministry of Science &amp; Technology, Government of India</a>
                                </p>
                                <p><a href="http://ableindia.in" target="_blank">The Association of Biotechnology Led Enterprises</a>
                                </p>

                            </div>
                        </div>
                    </div>
                    <!-- accordion item wrapper ends -->

                </div>
                <!-- accordion wrapper ends -->
                <!-- faqs end -->
                <div class="pageBreakBoth"></div>
            </div>
            <!-- page content wrapper ends -->

        </div>
        <!-- page wrapper ends -->

        <!-- footer wrapper starts -->
      
        <!-- footer wrapper ends -->

    </div>
    <!-- website wrapper ends -->
</body>
</html>
